TRAIL is a member of the TNF superfamily that can regulate cell apoptosis and entosis through binding to receptors TRAIL-R1/DR4 and TRAIL-R2/DR5.[45–48] So far, TRAIL has a wide range of investigations in oncology and shows significant potential as a novel target for biological anticancer drugs.[49] In our study, we observed that a genetically predicted higher circulating TRAIL level was related to a decreased CRC risk, which is supported by previous studies. The gene discussed is TNF; the disease is colorectal carcinoma.